Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	1583 people 4 RCTs in this analysis	At least 1 adverse effect with olanzapine (5–30 mg/day) with ziprasidone (40–160 mg/day) Absolute results not reported	RR 0.95 95% CI 0.85 to 1.07		Not significant
Systematic review	521 people Data from 1 RCT	Suicide attempt with olanzapine (7.5–30 mg/day) with ziprasidone (40–160 mg/day) Absolute results not reported	RR 1.10 95% CI 0.10 to 12.06		Not significant
Systematic review	245 people Data from 1 RCT	Suicide with olanzapine (7.5–30 mg/day) with ziprasidone (40–160 mg/day) Absolute results not reported	RR 0.25 95% CI 0.01 to 5.22		Not significant
Systematic review	1184 people 3 RCTs in this analysis	QTc prolongation with olanzapine (5–30 mg/day) with ziprasidone (40–160 mg/day) Absolute results not reported	RR 0.63 95% CI 0.04 to 9.93		Not significant
Systematic review	1372 people 4 RCTs in this analysis	QTc abnormalities: mean difference in change from baseline (ms) with olanzapine (5–30 mg/day) with ziprasidone (40–160 mg/day) Absolute results not reported	Mean difference –2.19 ms 95% CI –4.96 ms to +0.58 ms		Not significant
Systematic review	766 people 2 RCTs in this analysis	Sedation with olanzapine (7.5–30 mg/day) with ziprasidone (40–160 mg/day) Absolute results not reported	RR 1.56 95% CI 0.96 to 2.55		Not significant
Systematic review	766 people 2 RCTs in this analysis	Akathisia with olanzapine (7.5–30 mg/day) with ziprasidone (40–160 mg/day) Absolute results not reported	RR 0.71 95% CI 0.40 to 1.28		Not significant
Systematic review	548 people Data from 1 RCT	Dystonia with olanzapine (10–20 mg/day) with ziprasidone (80–160 mg/day) Absolute results not reported	RR 0.08 95% CI 0.00 to 1.33		Not significant
Systematic review	793 people 2 RCTs in this analysis	Extrapyramidal symptoms with olanzapine (7.5–30 mg) with ziprasidone (40–160 mg/day) Absolute results not reported	RR 0.53 95% CI 0.21 to 1.31		Not significant
Systematic review	1732 people 4 RCTs in this analysis	Use of antiparkinsonism medication with olanzapine (5–30 mg/day) with ziprasidone (40–160 mg/day) Absolute results not reported	RR 0.70 95% CI 0.50 to 0.97	Small effect size	olanzapine
Systematic review	925 people 2 RCTs in this analysis	Extrapyramidal symptoms: mean difference in Abnormal Involuntary Movement Scale with olanzapine (10–20 mg/day) with ziprasidone (80–160 mg/day) Absolute results not reported	Mean difference –0.16 95% CI –0.46 to +0.15		Not significant
Systematic review	924 people 2 RCTs in this analysis	Extrapyramidal symptoms: mean difference in Barnes Akathisia Scale with olanzapine (10–20 mg/day) with ziprasidone (80–160 mg/day) Absolute results not reported	Mean difference –0.07 95% CI –0.17 to +0.04		Not significant
Systematic review	269 people Data from 1 RCT	Extrapyramidal symptoms: mean difference in Extrapyramidal Symptom Rating Scale total score with olanzapine (5–15 mg/day) with ziprasidone (80–160 mg/day) Absolute results not reported	Mean difference –0.40 95% CI –1.53 to +0.73		Not significant
Systematic review	922 people 2 RCTs in this analysis	Extrapyramidal symptoms: mean difference in Simpson-Angus Scale with olanzapine (10–20 mg/day) with ziprasidone (80–160 mg/day) Absolute results not reported	Mean difference –0.34 95% CI –0.81 to +0.13		Not significant
Systematic review	394 people Data from 1 RCT	Abnormally high prolactin with olanzapine (10–20 mg/day) with ziprasidone (80–160 mg/day) Absolute results not reported	RR 1.12 95% CI 0.74 to 1.71		Not significant
Systematic review	766 people 2 RCTs in this analysis	Sexual dysfunction with olanzapine (7.5–30 mg/day) with ziprasidone (40–160 mg/day) Absolute results not reported	RR 1.33 95% CI 0.99 to 1.79		Not significant
Systematic review	1079 people 3 RCTs in this analysis	Mean difference in change from baseline in prolactin (ng/mL) with olanzapine (7.5–30 mg/day) with ziprasidone (40–160 mg/day) Absolute results not reported	Mean difference –0.20 ng/mL 95% CI –3.72 ng/mL to +3.33 ng/mL		Not significant
Systematic review	1502 people 2 RCTs in this analysis	Mean difference in change from baseline in cholesterol (mg/dL) with olanzapine (7.5–30 mg/day) with ziprasidone (40–160 mg/day) Absolute results not reported	Mean difference 15.83 mg/dL 95% CI 5.95 mg/dL to 25.72 mg/dL	Effect size not calculated	ziprasidone
Systematic review	1402 people 4 RCTs in this analysis	Mean difference in change from baseline in glucose (mg/dL) with olanzapine (7.5–30 mg/day) with ziprasidone (40–160 mg/day) Absolute results not reported	Mean difference 8.25 mg/dL 95% CI 2.77 mg/dL to 13.72 mg/dL	Effect size not calculated	ziprasidone
Systematic review	1708 people Data from 1 RCT	Weight gain with olanzapine (7.5–30 mg/day) with ziprasidone (40–160 mg/day) Absolute results not reported	RR 4.90 95% CI 3.38 to 7.12	Moderate effect size	ziprasidone
Systematic review	1659 people 5 RCTs in this analysis	Mean difference in change from baseline in weight (kg) with olanzapine with ziprasidone Absolute results not reported	Mean difference 3.82 kg 95% CI 2.96 kg to 4.69 kg	Effect size not calculated	ziprasidone